September 12, 2023 – Below is Tenet’s motion for final judgement against MPW tenant Steward for collection of DPP payments. We note the following passage of interest: “To the contrary, there is significant urgency to this Motion given the substantial risk that the passage of time
September 6, 2023 – Below is Viceroy’s first request for Discovery from Medical Properties Trust.
Hexagon fabricate a Divergent investment timeline, make increasingly poor disclosures, and are still stumped by the concept of corporate governance. PLEASE READ IMPORTANT DISCLAIMER – PAGE 5 August 8, 2023 – On July 19, 2023, Viceroy Research released a investigative report on Hexagon AB titled
July 28, 2023 – In further investigation of Hexagon’s subsidiaries, we highlight that “several ongoing tax audits” with “local taxing authorities” were highlighted by auditors EY in 2019. Not one other analyst appears to have acknowledged the significance or even questioned these audits/investigations. This has
July 26, 2023 – Viceroy Research is short Hexagon AB (STO: HEXA-B). On July 19, 2023 we published our report “Hexagon AB – Six Sides to Every Story”. That report exposed the egregious fraud and accounting irregularities occurring within the vast network of Hexagon entities.
July 24, 2023 – On Sunday, July 23, Greenbridge released a statement[1] in response to Viceroy Research’s report on Hexagon AB: Six Sides to Every Story (the Report). A copy of the Report can be found in the link below: https://viceroyresearch.org/2023/07/19/hexagon-ab-six-sides-to-every-story/ This note will dissect
Jul 20, 2023 – Attached is a letter Viceroy sent to Hexagon’s auditors, PwC, yesterday afternoon. It raises questions and requests for clarification on several accounting points.
July 19, 2023 – Viceroy Research is short Hexagon AB (STO: HEXA-B). Hexagon is a corporate dictatorship run by the majority owner and controlling voter: Melker Schörling. Melker-appointed Chairman & former Hexagon CEO, Ola Rollén, front-runs Hexagon investments through an investment vehicle that counts Schörling
June 21, 2023 – Viceroy have obtained the complaint by the United States against Medical Properties Trust (MPW), Olympia Health Care and Alecto Healthcare. The complaint alleges that Olympia failed to pay its debts to the government while making fraudulent payments to MPW and its parent
May 30, 2023 – Our research suggests that VSUN’s Europe entity, Vietnam Sunergy Europe GmbH (VSUN Europe) is likely operated entirely from Shanghai, China. The operations in Germany appear to be minimal and the company may be reselling competitor’s products. This is detailed in a
Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.
Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.
To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.
In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.
This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.
Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.
You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.
The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.